Evidence-based Practice

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials

Abstract

PURPOSE: To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: Computerized bibliographic searches with MEDLINE and CANCERLIT databases from 1980 through 2000 were supplemented with manual searches, with the keywords “hepatocellular carcinoma,” “liver cell carcinoma,” “randomized controlled trial [RCT],” and “chemoembolization.” Studies were included if patients with unresectable HCC were enrolled and if they were RCTs in which chemoembolization was compared with nonactive treatment (five RCTs) or if different transarterial modalities of therapy (13 RCTs) were compared. Data were extracted from each RCT according to the intention-to-treat method. Five of the RCTs with a nonactive treatment arm were combined by using the random-effects model, whereas all 18 RCTs were pooled from meta–regression analysis.

RESULTS: Chemoembolization significantly reduced the overall 2-year mortality rate (odds ratio, 0.54; 95% CI: 0.33, 0.89; P = .015) compared with nonactive treatment. Analysis of comparative RCTs helped to predict that overall mortality was significantly lower in patients treated with transarterial embolization (TAE) than in those treated with transarterial chemotherapy (odds ratio, 0.72; 95% CI: 0.53, 0.98; P = .039) and that there is no evidence that transarterial chemoembolization is more effective than TAE (odds ratio, 1.007; 95% CI: 0.79, 1.27; P = .95), which suggests that the addition of an anticancer drug did not improve the therapeutic benefit.

CONCLUSION: In patients with unresectable HCC, chemoembolization significantly improved the overall 2-year survival compared with nonactive treatment, but the magnitude of the benefit is relatively small.

References

1 El-Serang HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750. Crossref, Medline, Google Scholar
2 Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai Cl. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31:330-335. Crossref, Medline, Google Scholar
3 Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30:1434-1440. Crossref, Medline, Google Scholar
4 Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta-analysis? Aliment Pharmacol Ther 1998; 12:111-126. Crossref, Google Scholar
5 Koda M, Murawaki Y, Kawasaki H. The combination therapy of transcatheter arterial embolization and percutaneous ethanol injection for small hepatocellular carcinoma: randomized controlled study (abstr). J Hepatol 2000; 32:164. Crossref, Medline, Google Scholar
6 Lai E, Choi TK, Tong SW, Ong GB, Wong J. Treatment on unresectable hepatocellular carcinoma: results of a randomized controlled trial. World J Surg 1986; 10:501-509. Crossref, Medline, Google Scholar
7 Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 1988; 94:453-456. Crossref, Medline, Google Scholar
8 Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181-184. Crossref, Medline, Google Scholar
9 Madden MV, Krige JEJ, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34:1598-1600. Crossref, Medline, Google Scholar
10 Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787. Medline, Google Scholar
11 Lu C, Qi Y, Peng S. Lipiodolization with or without gelatin sponge in hepatic chemoembolization for hepatocellular carcinoma. Chin Med J (Engl) 1994; 107:209-215. Medline, Google Scholar
12 Groupe d’Étude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261. Crossref, Medline, Google Scholar
13 Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29:129-134. Crossref, Medline, Google Scholar
14 Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578- 1583. Crossref, Medline, Google Scholar
15 Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989; 97:965-971. Crossref, Medline, Google Scholar
16 Osaka Study Group on Hepatocellular Carcinoma. Studies on the chemotherapy with 5-fluorouracil in transcatheter chemoembolization (TAE) treated patients with resectable on non-resectable hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23(suppl):S29-S32. Crossref, Medline, Google Scholar
17 Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). Cancer Chemother Pharmacol 1992; 31(suppl 1):S1-S6. Crossref, Medline, Google Scholar
18 Okamura J, Kawai S, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study). Cancer Chemother Pharmacol 1992; 31(suppl 1):S20-S24. Crossref, Medline, Google Scholar
19 Ikeda K, Inoue H, Yano T, Kobayashi H, Nakajo M. Comparison of the anticancer effect ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection. Cancer Chemother Pharmacol 1992; 31(suppl 1):S65-S68. Crossref, Medline, Google Scholar
20 Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with lipiodol versus 4’-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33(suppl):S149-S152. Crossref, Medline, Google Scholar
21 Kawai S, Tani M, Okamura J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison between L-TAE with farmorubicin and L-TAE with adriamycin—preliminary results (second cooperative study). Cancer Chemother Pharmacol 1994; 33(suppl):S97-S102. Crossref, Medline, Google Scholar
22 Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 1994; 33(suppl):S93-S96. Google Scholar
23 Chang JM, Tzeng WS, Pan HB, Yang FC, Lai KH. Transcatheter arterial embolization with or without Cisplatin treatment of hepatocellular carcinoma. Cancer 1994; 74:2449-2453. Crossref, Medline, Google Scholar
24 Ikeda K, Saitoh S, Koida I, et al. A prospective randomized evaluation of a compound of Tegafur and Uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995; 18:204-210. Crossref, Medline, Google Scholar
25 Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995; 195:747-752. Link, Google Scholar
26 Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-lipiodol chemotherapy versus 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76:2202-2210. Crossref, Medline, Google Scholar
27 Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197:812- 818. Link, Google Scholar
28 Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997; 24(suppl 6):38-45. Google Scholar
29 Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intraarterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161. Medline, Google Scholar
30 Ikeda K, Saitoh S, Suzuki Y, et al. A prospective randomized administration of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1997; 20:202-208. Crossref, Medline, Google Scholar
31 Kwok PC, Lam TW, Chan SC, et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000; 32:955-964. Crossref, Medline, Google Scholar
32 Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20:295-301. Crossref, Medline, Google Scholar
33 Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P’eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82:122-126. Crossref, Medline, Google Scholar
34 Lygidakis NJ, Potoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre and post operative locoregional immunotherapy-chemotherapy—a prospective randomized study. Anticancer Res 1995; 15:543-550. Medline, Google Scholar
35 Kawata A, Une Y, Hosokawa M, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients: adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995; 18:257-262. Crossref, Medline, Google Scholar
36 Matsuda Y, Kawata S, Nagase T, et al. Interleukin-6 in transcatheter embolization for patients with hepatocellular carcinoma. Cancer 1994; 73:53-57. Crossref, Medline, Google Scholar
37 Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma: a randomized comparison. Am J Clin Oncol 1992; 15:37-40. Crossref, Medline, Google Scholar
38 Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991; 67:385-391. Crossref, Medline, Google Scholar
39 Rougier P, Pelletier G, Ducreux M, et al. Unresectable hepatocellular carcinoma: lack of efficacy of lipiodol chemoembolization—final results of a multicenter randomized trial (abstr). Proc Am Soc Clin Oncol 1997; 16:279A. Google Scholar
40 Pelletier G, Ducreux M, Broseta V, et al. Essai randomisé de la chimioembolisation lipiodolée dans le traitement du carcinome hépatocellulaire (CHC) non résectable (abstr). Gastroenterol Clin Biol 1996; 20:182A. Google Scholar
41 Bourguet P, Raoul JL, Guyader D. Randomised controlled trial of chemo-embolization vs intra-arterial injection of 131 I-labelled iodized oil (Lipiocis) in the treatment of hepatocellular carcinoma (abstr). Eur J Nucl Med 1994; 21:S52. Google Scholar
42 Bruix J, Llovet JM, Castells A, et al. Treatment of hepatocellular carcinoma by transarterial embolization (TAE): a prospective placebo controlled trial (abstr). Hepatology 1997; 26:249A. Google Scholar
43 Llovet JM, Real MI, Vilana R, et al. Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (abstr). J Hepatol 2001; 34:11A. Crossref, Medline, Google Scholar
44 Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430. Google Scholar
45 Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127:820-826. Crossref, Medline, Google Scholar
46 Nicolucci A, Grilli R, Alexanian AA, Apolone G, Torri W, Liberati A. Quality evolution and clinical implications of randomized, controlled trials on the treatment of lung cancer: a lost opportunity for meta-analysis. JAMA 1989; 262:2101-2107. Crossref, Medline, Google Scholar
47 Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282:1054-1060. Crossref, Medline, Google Scholar
48 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. Crossref, Medline, Google Scholar
49 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748. Medline, Google Scholar
50 Normand SL. Tutorial in biostatistics meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18:321-359. Crossref, Medline, Google Scholar
51 Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18:2693-2708. Crossref, Medline, Google Scholar
52 Yamashita Y, Torashima M, Oguni T, et al. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation. Abdom Imaging 1993; 18:352-356. Crossref, Medline, Google Scholar
53 Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993; 72:3202-3209. Crossref, Medline, Google Scholar
54 Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L’Hermine C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 1999; 172:59-64. Crossref, Medline, Google Scholar

Article History

Published in print: July 2002

Vol. 224, No. 1

Metrics

Downloaded 3,192 times

Altmetric Score